June 2021
Atherosclerosis is the underlying cause of cardiovascular disease.1 It is well-documented that low testosterone is associated with a large number of risk factors for atherosclerosis, and a growing number of studies show that testosterone has several beneficial effects on the cardiovascular system in men.2-6
We previously summarized the results of a 1-year double-blind, placebo-controlled randomized clinical trial (RCT) that investigated the effect of treatment with testosterone undecanoate injection on markers of insulin resistance, glycemic control, endothelial function and atherosclerosis.7 Here we present 2-year data from this study, showing that longer-term testosterone therapy results in further improvements compared to 1- year treatment.8,9
KEY POINTS
Carotid intima-media thickness (CIMT) is a validated noninvasive technique for measuring the atherosclerotic burden, and represents a surrogate measure of atherosclerosis.10,11 Multiple studies have shown that low testosterone is associated with increased CIMT in both middle-aged and older men.12-22 Importantly, low free testosterone has been found to be associated with progression of CIMT independent of age, and after adjustment for several cardiovascular risk factors (body mass index, waist- to-hip ratio, hypertension, diabetes, smoking and cholesterol levels).17
Unlike CIMT, which measures the extent of established carotid atherosclerosis, endothelial dysfunction is an early marker for atherosclerosis that can be detected before structural changes to the vessel wall appear.23 The most common non-invasive assessment of endothelial dysfunction is forearm flow mediated dilatation (FMD).24 Like CIMT, low testosterone has been found to be associated with endothelial dysfunction independent of age and other risk factors.25 The harmful effect of endothelial dysfunction on cardiovascular risk is elevated in the presence of hypogonadism,26 suggesting a protective effect of testosterone on the endothelium and blood vessels.
Both CIMT 27,28 and FMD 29,30 predict cardiovascular events and mortality, in some studies even after adjustment for age, sex, and vascular risk factors.31 Among previous studies that investigated the effect of testosterone therapy on markers of atherosclerosis (CIMT and coronary artery calcium score), most found a beneficial effect, especially on CIMT.32-35 Even young men (age 24-39 years) with idiopathic hypogonadotropic hypogonadism have higher CIMT and lower FMD compared to age-matched peers, and both CIMT and FMD is improved in this patient population with testosterone therapy.36
Long-term real-life evidence studies have shown that the health benefits of testosterone therapy occur progressively over time with continuous uninterrupted testosterone therapy, as explained in “Practical advice for effective testosterone therapy”. What follows is a summary of results achieved after 2 years of treatment with testosterone undecanoate injection on markers of insulin resistance, glycemic control, endothelial function and atherosclerosis, and a comparison with results achieved after 1 year.
Men (n=28) in the testosterone group continued to receive treatment with testosterone undecanoate injection (1000 mg i.m. every 10 weeks, after an initial interval of 6 weeks) for another year, and 2-year results were analysed and compared to 1-year results. All men had hypogonadism, obesity and type 2 diabetes. Results for year 1 and year 2 are given in table 1, and changes in CIMT, FMD and HOMA-IR are illustrated in figure 1.
Table 1: Results achieved year 1 and year 2 after treatment with testosterone undecanoate injection in men with hypogonadism, obesity and type 2 diabetes.8
Parameter | Baseline | Year 1 | Year 2 | Change after 1 year | Change after 2 years |
---|---|---|---|---|---|
BMI (kg/m2) | 34.03 | 33.25 | 32.45 | -0.80 | -1.59 |
Waist size (cm) | 116.48 | 114.9 | 112.96 | -1.58 | -3.51 |
FPG (mmol/L) | 10.06 | 8.83 | 8.23 | -1.23 | -1.83 |
HbA1c (%) | 8.12 | 7.18 | 6.60 | -0.94 | -1.51 |
HOMA-IR | 11.45 | 6.81 | 5.51 | -4.64 | -5.94 |
Total cholesterol (mmol/L) | 5.31 | 4.62 | 4.34 | -0.7 | -0.97 |
LDL (mmol/L) | 2.79 | 2.70 | 2.39 | -0.09 | -0.40 |
HDL (mmol/L) | 1.01 | 1.04 * | 1.15 | 0.03 * | 0.15 |
Triglycerides (nmol/L) | 2.86 | 2.32 * | 1.86 | -0.54 * | -0.99 |
FMD (%) | 4.68 | 7.07 | 7.14 | 2.40 | 2.46 |
CIMT (mm) | 0.89 | 0.79 | 0.73 | -0.10 | -0.14 |
* Not statistically significantly compared to baseline. All other changes are statistically significant.
Data from Groti Antonič K, Antonič B, Žuran I, Pfeifer M. Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). The aging male : the official journal of the International Society for the Study of the Aging Male. Dec 2020;23(5):1442-1454.
Figure 1: Effect on carotid intima-media thickness (CIMT) after year 1 and year 2 of treatment with testosterone undecanoate injection in men with hypogonadism, obesity and type 2 diabetes.8
CIMT = carotid intima-media thickness, FMD = flow mediated dilatation, HOMA-IR = Homeostatic Model Assessment for Insulin Resistance
Data from Groti Antonič K, Antonič B, Žuran I, Pfeifer M. Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). The aging male : the official journal of the International Society for the Study of the Aging Male. Dec 2020;23(5):1442-1454.
The 2-year report of this study also analysed changes in safety parameters. No cardiovascular adverse events occurred, and no patient was diagnosed with prostate cancer. As expected, hematocrit increased gradually during testosterone therapy (table 2). The rise in hematocrit did not exceed the upper limit of 0.52 at any time point for any subject. There was also a small elevation in PSA levels (table 2). Of 28 men in the testosterone group, 27 patients never had PSA >4 μg/L or a year-over-year increase of >1.4 μg/L. The single remaining study participant had been enrolled with pre-existing diagnosed BPH, confirmed by prostate biopsy, and was under regular supervision by a urologist, who deemed the BPH was not severe enough to warrant exclusion from the study. The patient’s baseline serum PSA was 4.0 μg/L, and did not change during the first year, but increased to 5.00 μg/L after the second year, resulting in termination of testosterone therapy.
Men in the placebo group (year 1) were switched to receive testosterone therapy in year 2. Of 27 men, 2 were diagnosed with BPH.
In one patient, PSA increased from 1.17 μg/L to 2.67 μg/L after 3 months, and again from 2.70 μg/L after 6 months to 5.20 μg/L after 12 months.
In the other patient, baseline PSA was 3.03 μg/L and remained steady until the 6-month mark, when it first rose >4.00 μg/L (to 4.04 lg/L), and then to 5.40 μg/L at 12 months.
Both patients discontinued testosterone therapy and underwent prostate biopsy; prostate cancer was excluded and BPH was diagnosed in both men.
Table 2: Change in hematocrit in men with obesity and hypogonadism and Type 2 Diabetes receiving treatment with testosterone undecanoate injection for 2 years.8,9
Time point | Hematocrit | PSA (μg/L) |
---|---|---|
Baseline | 0.427 | 0.645 |
3 months | 0.438 * | 0.700 * |
6 months | 0.449 | 0.735 |
12 months | 0.453 | 0.825 |
15 months | 0.456 | 0.970 |
18 months | 0.458 | 1.050 |
24 months | 0.460 | 1.175 |
* Not statistically significantly compared to baseline. All other changes are statistically significant.
Data from:
Groti Antonič K, Antonič B, Žuran I, Pfeifer M. Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). The aging male : the official journal of the International Society for the Study of the Aging Male. Dec 2020;23(5):1442-1454.
Groti Antonič K, Antonič B, Pfeifer M. Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial. Androgens: Clinical Research and Therapeutics. 2020/10/01 2020;1(1):85-93.
The study concluded that treatment with testosterone undecanoate injection for 2 years, compared to 1 year, resulted in further improvements in CIMT, FMD, BMI, waist size, HbA1c, triglycerides, LDL and HDL cholesterol. Additional longer-term studies on effects of testosterone therapy on atherosclerosis, endothelial function and insulin resistance are warranted.
The 2-year data summarized above show that uninterrupted treatment with testosterone undecanoate injection results in further improvements in markers of insulin resistance, glycemic control, endothelial function and atherosclerosis. It is noteworthy that the increase in HDL and reduction in triglycerides did not become statistically significant until after 2 years of testosterone therapy. This confirms the importance of longer-term treatment when evaluating the benefits of testosterone therapy in men with hypogonadism.
Furthermore, the present study confirmed the safety of treatment with testosterone undecanoate injection, showing that there were no cases of adverse cardiovascular events nor prostate cancer. Hematocrit stayed below 52% in all men, and PSA remained below PSA >4 μg/L and never exceeded a year-over-year increase of >1.4 μg/L in the majority of men.
In contrast to most previous studies investigating the effect of testosterone therapy on atherosclerosis,32-36 in the TEAAM (Testosterone’s Effects on Atherosclerosis Progression in Aging Men) trial, testosterone therapy did not affect markers of atherosclerosis (intima-media thickness and coronary artery calcium score).35 However, in men not taking statins, one marker of atherosclerosis (coronary artery calcium) was significantly lower in the testosterone group than in the placebo group. For more information about this study, see “Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men”
In the present study, most subjects were taking statins and hypertension medications, which may explain the reduction in CIMT in the placebo group. Nevertheless, the reduction in CIMT was twice as large among men treated with testosterone (from 0.89 to 0.79, -0.10) compared to those treated with placebo (from 0.83 to 0.78, -0.05). In another 2-year study, treatment with testosterone undecanoate for 1 year reduced CIMT by -0.22 mm (from a baseline value of 1.03).33 The greater baseline CIMT suggests that the reduction in CIMT with testosterone therapy is greater in men with more severe atherosclerosis.
To put this in perspective, one can compare the reductions in CIMT after testosterone therapy with that seen in statin trials. In the ARBITER trial, atorvastatin reduced CIMT by only -0.034 after 1 year.37 Hence, testosterone therapy is a promising treatment in men with hypogonadism, who are at increased risk of heart disease.4 Indeed, long-term treatment with testosterone undecanoate for 8 years has been shown to reduce mortality by 66% and 92%, as well as non-fatal heart attacks and strokes, compared to men not receiving testosterone therapy.38-41
A previous study showed that treatment with testosterone undecanoate injection for 5 years in men with hypogonadism, obesity and type 2 diabetes reduced incidence of recurrent stroke and mortality.42 For more information, see “Hypogonadism and testosterone treatment following stroke in men with type 2 diabetes” It is presumable that reduction in atherosclerosis, endothelial dysfunction and insulin resistance, as shown in the present study, contributed to the reduced incidence of recurrent stroke and mortality.